Sanovas has filed Vas Zeppelin Smart Catheter's application with the US Food and Drug Administration (FDA) for approval.
The miniaturized interventional catheter, which the company claims is the smallest interventional catheters commercially available, features a portfolio of integrated tools and sensors.
Designed for operating on a breathing lung, the technology minimizes the procedural risks associated with pulmonary intervention including damage to the treatment site and/or post-operative complications.
Sanovas CEO Larry Gerrans said, "With one in seven Americans suffering from chronic pulmonary disease and with lung cancer killing more people than breast, prostate and colon cancers combined, new technologies aimed at the earliest stages of lung disease are desperately needed."
The miniaturized catheter, which is intended to synergize access, 3D imaging, physiologic metrics, on-board diagnostics and related therapy, will remove obstructions and deliver drug and immune therapies to the smallest and most remote passageways in the human body
The launch of Vas Zeppelin will also serve as the cornerstone to the Sanovas’s arsenal of therapy enabling solutions, claims the company.
In addition, the company will actively file for clearance of its follow on technologies in the coming months.